In September 2025, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) published a new position paper addressing the possibilities of revitalising the antibiotic pipelines through pull incentive. The document builds on the outcomes of the 2024 UN High-Level Meeting on Antimicrobial Resistance (AMR) and its political declaration, as well as the biennial AMR Ministerial Meeting. It paves the way for progress ahead of the next UN High-Level Meeting on AMR in 2029.
In this instance, a central priority is establishing the necessary policy frameworks to stimulate R&D investment. However, there are still key barriers to antibiotic R&D and policy measures that need to be address. The IFPMA also highlights the urgent need for effective pull incentives to ensure a reliable pipeline of new antibiotics for patients and health systems. The position paper sets out a number of core principles for designing and implementing the proposed incentives.